Can-Fite BioPharma (NYSE:CANF) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research note released on Monday morning. The firm issued a sell rating on the stock.

CANF has been the subject of a number of other reports. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Can-Fite BioPharma in a research report on Tuesday, November 12th. D. Boral Capital reiterated a “buy” rating and set a $10.00 price target on shares of Can-Fite BioPharma in a report on Tuesday, December 31st.

Can-Fite BioPharma Stock Down 1.4 %

NYSE:CANF opened at $1.46 on Monday. Can-Fite BioPharma has a twelve month low of $1.29 and a twelve month high of $4.69. The stock’s 50-day simple moving average is $1.63 and its 200 day simple moving average is $2.14. The firm has a market capitalization of $5.17 million, a PE ratio of -0.82 and a beta of 1.33.

Hedge Funds Weigh In On Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers raised its stake in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 26,880 shares of the company’s stock after purchasing an additional 9,935 shares during the period. Rhumbline Advisers owned 0.76% of Can-Fite BioPharma worth $44,000 at the end of the most recent quarter. Institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.